Section 24 of the Constitution of Australia

Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

Retrieved on: 
화요일, 4월 11, 2023
Orange County Convention Center, LSD1, Radiation, Temozolomide, GBM, American Association for Cancer Research, Glioblastoma, GL261, Section 24 of the Constitution of Australia, Standard of care, Cancer, Orphan, Immunology, FDA, Therapy, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Immunotherapy

STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.

Key Points: 
  • STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.
  • The conference will take place on April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
  • Dr Konrad Koehler, Head of Discovery, will present a poster entitled Potentiation of Immunotherapy by LSD1 Modulation on Sunday April 16, 2023, at 1:30 PM – 5:00 PM.
  • Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.

Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

Retrieved on: 
화요일, 4월 11, 2023
Orange County Convention Center, LSD1, Radiation, Temozolomide, GBM, American Association for Cancer Research, Glioblastoma, GL261, Section 24 of the Constitution of Australia, Standard of care, Cancer, Orphan, Immunology, FDA, Therapy, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Immunotherapy

STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.

Key Points: 
  • STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.
  • The conference will take place on April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
  • Dr Konrad Koehler, Head of Discovery, will present a poster entitled Potentiation of Immunotherapy by LSD1 Modulation on Sunday April 16, 2023, at 1:30 PM – 5:00 PM.
  • Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.

Proclamation of a constitutional amendment issued to repeal outdated tax exemption

Retrieved on: 
금요일, 5월 6, 2022
RSS, Investment, Commons, Government of Canada, Legislative Assembly of Saskatchewan, Section 24 of the Constitution of Australia, Twitter, Palace of Westminster, The Right Honourable, House, Government, Privy council, Time, Justice, Constitution, House of Commons of Canada, Parliament, CPR, Canada's grand railway hotels, Queen's Privy Council for Canada, Minister of Intergovernmental Affairs (Canada), The Honourable, Saskatchewan Act, Queen, Legislative assembly, News, Senate, Community, Oil, Health insurance, Property management

By repealing section 24, the constitutional amendment removes an outdated tax exemption from 1880 that was benefitting the Canadian Pacific Railway (CPR) which recognized CPR's investments in building the trans-Canadian rail line in the 19th century.

Key Points: 
  • By repealing section 24, the constitutional amendment removes an outdated tax exemption from 1880 that was benefitting the Canadian Pacific Railway (CPR) which recognized CPR's investments in building the trans-Canadian rail line in the 19th century.
  • This constitutional amendment was reached using the bilateral constitutional amending procedure.
  • "This constitutional amendment was initiated by the Legislative Assembly of Saskatchewan and approved by both Houses of Parliament.
  • This constitutional amendment removes certain outdated tax exemptions and will uphold a just taxation system for residents and businesses."

New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services

Retrieved on: 
금요일, 4월 8, 2022
Surface plasmon resonance, Company, Section 23, AM, Syngenic, Central Waqf Council, PM, 2D, Section 27 of the Canadian Charter of Rights and Freedoms, Systems biology, 3D, Section 40 of the Constitution of Australia, Section 39 of the Constitution of Australia, Comparison, PCR, Section 4, KRAS, AACR, Reaction, American Association, Neoplasm, 2021 Essex County Council election, Section 8, Association, American Association for Cancer Research, Section 24 of the Constitution of Australia, CDK, CRO, Section 11 of the Canadian Charter of Rights and Freedoms, Drug discovery, LRRK2, Section 5, Protein kinase, Pharmaceutical industry, Powder metallurgy, Electric motor, Online gambling

MALVERN, Pa., April 8, 2022 /PRNewswire/ -- Reaction Biology ("Reaction" or the "Company"), an industry- leading provider of drug discovery services, today announced that twelve abstracts highlighting data from the Company's oncology drug discovery services platform will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13, 2022, in New Orleans, Louisiana.

Key Points: 
  • "At AACR 2022, we look forward to showcasing data from our comprehensive suite of innovative drug discovery services that continue to support our clients in their oncology research goals," said Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology.
  • "With these data, we continue to build upon our capabilities as a world leader and partner in drug discovery."
  • Reaction will present data from a number of new and enhanced assays and other drug discovery services in oncology.
  • "These data at AACR represent the breadth and depth of Reaction Biology's pre-clinical research services in oncology and underscore why we are a preferred global partner in the area of drug discovery."